A fundamental patent for a unique nanoparticle-based immune delivery system (Myeloid Targeting Platform) selective for macrophages and dendritic cells is granted in Japan

July 23rd, 2024 | Press Release

United Immunity, Co., Ltd. is an innovative biotech company with drug candidates for refractory cancer and other cancers using our proprietary nanoparticle drug delivery technology (Myeloid Targeting PlatformTM), which is selective for macrophages and dendritic cells. A patent application (PCT/JP2022/030928; JP2023-534246 “Cancer Therapeutic Agent”) protecting the relationship between our nanoparticles and its target receptor DC-SIGN has recently been granted a patent in Japan. We will continue to protect our platform technology on a global basis, with the aim of obtaining patent rights in the US, Europe and other countries as soon as possible.

Back to Press releases

We want to provide you with the most important information and services in the best possible way. In order to do this, we need your consent to use the web analysis tool »Google Analytics« to create and evaluate an anonymous analysis of your visit for statistical purposes. You can change your consent at any time on the data protection page, otherwise it will remain valid for twelve months.